DE3226768A1
(de)
|
1981-11-05 |
1983-05-26 |
Hoechst Ag, 6230 Frankfurt |
Derivate der cis, endo-2-azabicyclo-(3.3.0)-octan-3-carbonsaeure, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung
|
DE3211676A1
(de)
|
1982-03-30 |
1983-10-06 |
Hoechst Ag |
Neue derivate von cycloalka (c) pyrrol-carbonsaeuren, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung sowie neue cycloalka (c) pyrrol-carbonsaeuren als zwischenstufen und verfahren zu deren herstellung
|
US4499082A
(en)
|
1983-12-05 |
1985-02-12 |
E. I. Du Pont De Nemours And Company |
α-Aminoboronic acid peptides
|
FR2575753B1
(fr)
|
1985-01-07 |
1987-02-20 |
Adir |
Nouveaux derives peptidiques a structure polycyclique azotee, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
|
US5496927A
(en)
|
1985-02-04 |
1996-03-05 |
Merrell Pharmaceuticals Inc. |
Peptidase inhibitors
|
DE3683541D1
(de)
|
1985-06-07 |
1992-03-05 |
Ici America Inc |
Selektionierte difluorverbindungen.
|
US5231084A
(en)
|
1986-03-27 |
1993-07-27 |
Hoechst Aktiengesellschaft |
Compounds having a cognition adjuvant action, agents containing them, and the use thereof for the treatment and prophylaxis of cognitive dysfuncitons
|
US5736520A
(en)
|
1988-10-07 |
1998-04-07 |
Merrell Pharmaceuticals Inc. |
Peptidase inhibitors
|
NZ235155A
(en)
|
1989-09-11 |
1993-04-28 |
Merrell Dow Pharma |
Peptidase substrates in which the carboxy terminal group has been replaced by a tricarbonyl radical
|
US5371072A
(en)
|
1992-10-16 |
1994-12-06 |
Corvas International, Inc. |
Asp-Pro-Arg α-keto-amide enzyme inhibitors
|
EP0604182B1
(en)
|
1992-12-22 |
2000-10-11 |
Eli Lilly And Company |
Inhibitors of HIV protease useful for the treatment of Aids
|
DK0727419T3
(da)
|
1992-12-29 |
2002-06-10 |
Abbott Lab |
Mellemprodukter til fremstilling af forbindelser, som inhiberer retroviral protease
|
US5384410A
(en)
|
1993-03-24 |
1995-01-24 |
The Du Pont Merck Pharmaceutical Company |
Removal of boronic acid protecting groups by transesterification
|
US5656600A
(en)
|
1993-03-25 |
1997-08-12 |
Corvas International, Inc. |
α-ketoamide derivatives as inhibitors of thrombosis
|
US5672582A
(en)
|
1993-04-30 |
1997-09-30 |
Merck & Co., Inc. |
Thrombin inhibitors
|
IL110752A
(en)
|
1993-09-13 |
2000-07-26 |
Abbott Lab |
Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
|
US5559158A
(en)
|
1993-10-01 |
1996-09-24 |
Abbott Laboratories |
Pharmaceutical composition
|
US5468858A
(en)
|
1993-10-28 |
1995-11-21 |
The Board Of Regents Of Oklahoma State University Physical Sciences |
N-alkyl and n-acyl derivatives of 3,7-diazabicyclo-[3.3.1]nonanes and selected salts thereof as multi-class antiarrhythmic agents
|
IL111991A
(en)
|
1994-01-28 |
2000-07-26 |
Abbott Lab |
Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
|
AU1615895A
(en)
|
1994-03-31 |
1995-10-12 |
Bristol-Myers Squibb Company |
Imidazole-containing inhibitors of farnesyl protein transferase
|
US5847135A
(en)
|
1994-06-17 |
1998-12-08 |
Vertex Pharmaceuticals, Incorporated |
Inhibitors of interleukin-1β converting enzyme
|
US5756466A
(en)
|
1994-06-17 |
1998-05-26 |
Vertex Pharmaceuticals, Inc. |
Inhibitors of interleukin-1β converting enzyme
|
US6420522B1
(en)
|
1995-06-05 |
2002-07-16 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of interleukin-1β converting enzyme
|
US5716929A
(en)
|
1994-06-17 |
1998-02-10 |
Vertex Pharmaceuticals, Inc. |
Inhibitors of interleukin-1β converting enzyme
|
US5861267A
(en)
|
1995-05-01 |
1999-01-19 |
Vertex Pharmaceuticals Incorporated |
Methods, nucleotide sequences and host cells for assaying exogenous and endogenous protease activity
|
US6037157A
(en)
|
1995-06-29 |
2000-03-14 |
Abbott Laboratories |
Method for improving pharmacokinetics
|
WO1997019084A1
(en)
|
1995-11-23 |
1997-05-29 |
Merck Sharp & Dohme Limited |
Spiro-piperidine derivatives and their use as tachykinin antagonists
|
US5807876A
(en)
|
1996-04-23 |
1998-09-15 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of IMPDH enzyme
|
US6054472A
(en)
|
1996-04-23 |
2000-04-25 |
Vertex Pharmaceuticals, Incorporated |
Inhibitors of IMPDH enzyme
|
ZA972195B
(en)
|
1996-03-15 |
1998-09-14 |
Du Pont Merck Pharma |
Spirocycle integrin inhibitors
|
CN1116288C
(zh)
|
1996-04-23 |
2003-07-30 |
沃泰克斯药物股份有限公司 |
用作肌苷-5'-一磷酸脱氢酶抑制剂的脲衍生物
|
US5990276A
(en)
|
1996-05-10 |
1999-11-23 |
Schering Corporation |
Synthetic inhibitors of hepatitis C virus NS3 protease
|
AU2933797A
(en)
|
1996-05-10 |
1997-12-05 |
Schering Corporation |
Synthetic inhibitors of hepatitis c virus ns3 protease
|
US6153579A
(en)
|
1996-09-12 |
2000-11-28 |
Vertex Pharmaceuticals, Incorporated |
Crystallizable compositions comprising a hepatitis C virus NS3 protease domain/NS4A complex
|
AU723414B2
(en)
|
1996-09-25 |
2000-08-24 |
Merck Sharp & Dohme Limited |
Spiro-azacyclic derivatives, their preparation and their use as tachykinin antagonists
|
EP1021426B1
(en)
|
1996-10-08 |
2003-09-17 |
Colorado State University Research Foundation |
Catalytic asymmetric epoxidation
|
JP4080541B2
(ja)
|
1996-10-18 |
2008-04-23 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
セリンプロテアーゼ、特にc型肝炎ウイルスns3プロテアーゼの阻害因子
|
GB9623908D0
(en)
|
1996-11-18 |
1997-01-08 |
Hoffmann La Roche |
Amino acid derivatives
|
DE19648011A1
(de)
|
1996-11-20 |
1998-05-28 |
Bayer Ag |
Cyclische Imine
|
DE69816280T2
(de)
|
1997-03-14 |
2004-05-27 |
Vertex Pharmaceuticals Inc., Cambridge |
Inhibitoren des impdh-enzyms
|
GB9708484D0
(en)
|
1997-04-25 |
1997-06-18 |
Merck Sharp & Dohme |
Therapeutic agents
|
GB9711114D0
(en)
|
1997-05-29 |
1997-07-23 |
Merck Sharp & Dohme |
Therapeutic agents
|
EP1012180B1
(en)
|
1997-08-11 |
2004-12-01 |
Boehringer Ingelheim (Canada) Ltd. |
Hepatitis c inhibitor peptide analogues
|
US6767991B1
(en)
|
1997-08-11 |
2004-07-27 |
Boehringer Ingelheim (Canada) Ltd. |
Hepatitis C inhibitor peptides
|
US6183121B1
(en)
|
1997-08-14 |
2001-02-06 |
Vertex Pharmaceuticals Inc. |
Hepatitis C virus helicase crystals and coordinates that define helicase binding pockets
|
US20040058982A1
(en)
|
1999-02-17 |
2004-03-25 |
Bioavailability System, Llc |
Pharmaceutical compositions
|
US20020017295A1
(en)
|
2000-07-07 |
2002-02-14 |
Weers Jeffry G. |
Phospholipid-based powders for inhalation
|
WO1999028482A2
(en)
|
1997-11-28 |
1999-06-10 |
Schering Corporation |
Single-chain recombinant complexes of hepatitis c virus ns3 protease and ns4a cofactor peptide
|
ES2281170T3
(es)
|
1998-03-31 |
2007-09-16 |
Vertex Pharmaceuticals Incorporated |
Inhibidores de serina proteasas, particularmente proteasa ns3 del virus de la hepatitis c.
|
US6251583B1
(en)
|
1998-04-27 |
2001-06-26 |
Schering Corporation |
Peptide substrates for HCV NS3 protease assays
|
GB9812523D0
(en)
|
1998-06-10 |
1998-08-05 |
Angeletti P Ist Richerche Bio |
Peptide inhibitors of hepatitis c virus ns3 protease
|
US6323180B1
(en)
|
1998-08-10 |
2001-11-27 |
Boehringer Ingelheim (Canada) Ltd |
Hepatitis C inhibitor tri-peptides
|
DE19836514A1
(de)
|
1998-08-12 |
2000-02-17 |
Univ Stuttgart |
Modifikation von Engineeringpolymeren mit N-basischen Gruppe und mit Ionenaustauschergruppen in der Seitenkette
|
US6117639A
(en)
|
1998-08-31 |
2000-09-12 |
Vertex Pharmaceuticals Incorporated |
Fusion proteins, DNA molecules, vectors, and host cells useful for measuring protease activity
|
US6025516A
(en)
|
1998-10-14 |
2000-02-15 |
Chiragene, Inc. |
Resolution of 2-hydroxy-3-amino-3-phenylpropionamide and its conversion to C-13 sidechain of taxanes
|
ES2306646T3
(es)
|
1999-02-09 |
2008-11-16 |
Pfizer Products Inc. |
Composiciones de farmacos basicos con biodisponibilidad incrementada.
|
US20020042046A1
(en)
|
1999-02-25 |
2002-04-11 |
Vertex Pharmaceuticals, Incorporated |
Crystallizable compositions comprising a hepatitis C virus NS3 protease domain/NS4A complex
|
IL145475A0
(en)
|
1999-03-19 |
2002-06-30 |
Vertex Pharma |
Compounds that inhibit impdh enzyme and pharmaceutical compositions containing the same
|
US6608027B1
(en)
|
1999-04-06 |
2003-08-19 |
Boehringer Ingelheim (Canada) Ltd |
Macrocyclic peptides active against the hepatitis C virus
|
US7122627B2
(en)
|
1999-07-26 |
2006-10-17 |
Bristol-Myers Squibb Company |
Lactam inhibitors of Hepatitis C virus NS3 protease
|
US20020183249A1
(en)
|
1999-08-31 |
2002-12-05 |
Taylor Neil R. |
Method of identifying inhibitors of CDC25
|
GB9925955D0
(en)
|
1999-11-02 |
1999-12-29 |
Angeletti P Ist Richerche Bio |
Hcv n33 protease inhibitors
|
CA2390349A1
(en)
|
1999-12-03 |
2001-06-07 |
Bristol-Myers Squibb Pharma Company |
Alpha-ketoamide inhibitors of hepatitis c virus ns3 protease
|
AU2001234837A1
(en)
|
2000-02-08 |
2001-08-20 |
Schering Corporation |
Azapeptides useful in the treatment of hepatitis c
|
WO2001064678A2
(en)
|
2000-02-29 |
2001-09-07 |
Bristol-Myers Squibb Pharma Company |
Inhibitors of hepatitis c virus ns3 protease
|
AU2001251165A1
(en)
|
2000-04-03 |
2001-10-15 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
|
AR029903A1
(es)
|
2000-04-05 |
2003-07-23 |
Schering Corp |
Inhibidores macrociclicos de la ns3-serina proteasa, del virus de la hepatitis c, que comprenden partes p2 n-ciclicas, composiciones farmaceuticas y utilizacion de los mismos para la manufactura de un medicamento
|
CN1432022A
(zh)
|
2000-04-19 |
2003-07-23 |
先灵公司 |
含有烷基和芳基丙氨酸p2部分的丙型肝炎病毒的大环ns3-丝氨酸蛋白酶抑制剂
|
AU2001267886A1
(en)
|
2000-06-30 |
2002-01-14 |
Seikagaku Corporation |
Epoxycarboxylic acid amides, azides and amino alcohols and processes for preparation of alpha-keto amides by using them
|
US7244721B2
(en)
|
2000-07-21 |
2007-07-17 |
Schering Corporation |
Peptides as NS3-serine protease inhibitors of hepatitis C virus
|
WO2002008251A2
(en)
|
2000-07-21 |
2002-01-31 |
Corvas International, Inc. |
Peptides as ns3-serine protease inhibitors of hepatitis c virus
|
CZ2003195A3
(cs)
|
2000-07-21 |
2003-04-16 |
Schering Corporation |
Peptidové inhibitory serinové proteázy NS3 a farmaceutický prostředek
|
AR034127A1
(es)
|
2000-07-21 |
2004-02-04 |
Schering Corp |
Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento
|
US7012066B2
(en)
|
2000-07-21 |
2006-03-14 |
Schering Corporation |
Peptides as NS3-serine protease inhibitors of hepatitis C virus
|
AR029851A1
(es)
|
2000-07-21 |
2003-07-16 |
Dendreon Corp |
Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
|
US6777400B2
(en)
|
2000-08-05 |
2004-08-17 |
Smithkline Beecham Corporation |
Anti-inflammatory androstane derivative compositions
|
SV2003000617A
(es)
|
2000-08-31 |
2003-01-13 |
Lilly Co Eli |
Inhibidores de la proteasa peptidomimetica ref. x-14912m
|
US6939692B2
(en)
|
2000-09-12 |
2005-09-06 |
Degussa Ag |
Nucleotide sequences coding for the pknB gene
|
US6846806B2
(en)
|
2000-10-23 |
2005-01-25 |
Bristol-Myers Squibb Company |
Peptide inhibitors of Hepatitis C virus NS3 protein
|
HUP0500456A3
(en)
|
2000-11-20 |
2012-05-02 |
Bristol Myers Squibb Co |
Hepatitis c tripeptide inhibitors, pharmaceutical compositions comprising thereof and their use
|
MXPA03005219A
(es)
|
2000-12-12 |
2003-09-25 |
Schering Corp |
Peptidos diarilicos como inhibidores de ns3-serina proteasa en hepatitis de virus c.
|
US6653295B2
(en)
|
2000-12-13 |
2003-11-25 |
Bristol-Myers Squibb Company |
Inhibitors of hepatitis C virus NS3 protease
|
US6727366B2
(en)
|
2000-12-13 |
2004-04-27 |
Bristol-Myers Squibb Pharma Company |
Imidazolidinones and their related derivatives as hepatitis C virus NS3 protease inhibitors
|
WO2002057287A2
(en)
|
2001-01-22 |
2002-07-25 |
Merck & Co., Inc. |
Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
|
GB0102342D0
(en)
|
2001-01-30 |
2001-03-14 |
Smithkline Beecham Plc |
Pharmaceutical formulation
|
MXPA03006794A
(es)
|
2001-01-30 |
2003-11-13 |
Vertex Pharma |
Un analisis cuantitativo para acidos nucleicos.
|
JP4499990B2
(ja)
|
2001-03-27 |
2010-07-14 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Hcv感染に有用な組成物および方法
|
GB0107924D0
(en)
|
2001-03-29 |
2001-05-23 |
Angeletti P Ist Richerche Bio |
Inhibitor of hepatitis C virus NS3 protease
|
EP1463699A2
(en)
|
2001-07-03 |
2004-10-06 |
ALTANA Pharma AG |
Process for the production of 3-phenylisoserine
|
ATE349463T1
(de)
|
2001-07-11 |
2007-01-15 |
Vertex Pharma |
Verbrückte bizyklische serinproteaseinhibitoren
|
JP2003055389A
(ja)
|
2001-08-09 |
2003-02-26 |
Univ Tokyo |
錯体及びそれを用いたエポキシドの製法
|
US6824769B2
(en)
|
2001-08-28 |
2004-11-30 |
Vertex Pharmaceuticals Incorporated |
Optimal compositions and methods thereof for treating HCV infections
|
NZ531681A
(en)
|
2001-10-24 |
2007-05-31 |
Vertex Pharma |
Inhibitors of serine protease, particularly hepatitis C virus NS3-NS4A protease, incorporating a fused ring system
|
ES2234451T1
(es)
|
2001-11-14 |
2005-07-01 |
Teva Pharmaceutical Industries Ltd. |
Formas cristalinas y amorfas de losartan potasio y procedimiento para su preparacion.
|
CA2369711A1
(en)
|
2002-01-30 |
2003-07-30 |
Boehringer Ingelheim (Canada) Ltd. |
Macrocyclic peptides active against the hepatitis c virus
|
US6642204B2
(en)
|
2002-02-01 |
2003-11-04 |
Boehringer Ingelheim International Gmbh |
Hepatitis C inhibitor tri-peptides
|
CA2369970A1
(en)
|
2002-02-01 |
2003-08-01 |
Boehringer Ingelheim (Canada) Ltd. |
Hepatitis c inhibitor tri-peptides
|
CA2370396A1
(en)
|
2002-02-01 |
2003-08-01 |
Boehringer Ingelheim (Canada) Ltd. |
Hepatitis c inhibitor tri-peptides
|
AR038375A1
(es)
|
2002-02-01 |
2005-01-12 |
Pfizer Prod Inc |
Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
|
US7091184B2
(en)
|
2002-02-01 |
2006-08-15 |
Boehringer Ingelheim International Gmbh |
Hepatitis C inhibitor tri-peptides
|
NZ561851A
(en)
|
2002-04-11 |
2009-05-31 |
Vertex Pharma |
Inhibitors of serine proteases, particularly hepatitis C virus NS3 - NS4 protease
|
CA2494340C
(en)
|
2002-08-01 |
2012-01-24 |
Pharmasset Inc. |
Compounds with the bicyclo[4.2.1]nonane system for the treatment of flaviviridae infections
|
US20050075279A1
(en)
|
2002-10-25 |
2005-04-07 |
Boehringer Ingelheim International Gmbh |
Macrocyclic peptides active against the hepatitis C virus
|
CA2413705A1
(en)
|
2002-12-06 |
2004-06-06 |
Raul Altman |
Use of meloxicam in combination with an antiplatelet agent for treatment of acute coronary syndrome and related conditions
|
US7601709B2
(en)
|
2003-02-07 |
2009-10-13 |
Enanta Pharmaceuticals, Inc. |
Macrocyclic hepatitis C serine protease inhibitors
|
US7223785B2
(en)
|
2003-01-22 |
2007-05-29 |
Boehringer Ingelheim International Gmbh |
Viral polymerase inhibitors
|
US7098231B2
(en)
|
2003-01-22 |
2006-08-29 |
Boehringer Ingelheim International Gmbh |
Viral polymerase inhibitors
|
US20040180815A1
(en)
|
2003-03-07 |
2004-09-16 |
Suanne Nakajima |
Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors
|
KR100940619B1
(ko)
|
2003-02-07 |
2010-02-05 |
이난타 파마슈티칼스, 인코포레이티드 |
마크로사이클릭 씨형 간염 세린 단백효소 억제제
|
JP2006517960A
(ja)
|
2003-02-18 |
2006-08-03 |
ファイザー インコーポレイテッド |
C型肝炎ウイルスの阻害剤、それを使用する組成物および治療法
|
EP1601685A1
(en)
|
2003-03-05 |
2005-12-07 |
Boehringer Ingelheim International GmbH |
Hepatitis c inhibiting compounds
|
DE602004029866D1
(de)
|
2003-03-05 |
2010-12-16 |
Boehringer Ingelheim Pharma |
Peptidanaloga mit inhibitorischer wirkung auf hepatitis c
|
CA2521678A1
(en)
|
2003-04-11 |
2004-10-28 |
Vertex Pharmaceuticals, Incorporated |
Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
|
TW200510391A
(en)
|
2003-04-11 |
2005-03-16 |
Vertex Pharma |
Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
|
PT1654261E
(pt)
|
2003-05-21 |
2008-01-18 |
Boehringer Ingelheim Int |
Compostos inibidores da hepatite c
|
EP1646642A2
(en)
|
2003-07-18 |
2006-04-19 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
|
WO2005018330A1
(en)
|
2003-08-18 |
2005-03-03 |
Pharmasset, Inc. |
Dosing regimen for flaviviridae therapy
|
TW201127828A
(en)
|
2003-09-05 |
2011-08-16 |
Vertex Pharma |
Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
|
AU2004272114B2
(en)
|
2003-09-12 |
2010-11-04 |
Vertex Pharmaceuticals Incorporated |
Animal model for protease activity and liver damage
|
EP1664091A1
(en)
|
2003-09-18 |
2006-06-07 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
|
US6933760B2
(en)
|
2003-09-19 |
2005-08-23 |
Intel Corporation |
Reference voltage generator for hysteresis circuit
|
DE602004031645D1
(de)
|
2003-09-22 |
2011-04-14 |
Boehringer Ingelheim Pharma |
Makrozyklische peptide mit wirkung gegen das hepatitis-c-virus
|
CA2541634A1
(en)
|
2003-10-10 |
2005-04-28 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
|
AR045870A1
(es)
|
2003-10-11 |
2005-11-16 |
Vertex Pharma |
Terapia de combinacion para la infeccion de virus de hepatitis c
|
KR20060120166A
(ko)
|
2003-10-27 |
2006-11-24 |
버텍스 파마슈티칼스 인코포레이티드 |
Hcv ns3-ns4a 단백질분해효소 저항성 돌연변이
|
US8187874B2
(en)
|
2003-10-27 |
2012-05-29 |
Vertex Pharmaceuticals Incorporated |
Drug discovery method
|
KR20060120162A
(ko)
|
2003-10-27 |
2006-11-24 |
버텍스 파마슈티칼스 인코포레이티드 |
Hcv 치료용 배합물
|
JP4942485B2
(ja)
|
2003-10-28 |
2012-05-30 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Fischer−fink型合成および続くアシル化による4,5−ジアルキル−3−アシル−ピロール−2−カルボン酸誘導体の製造
|
US20050119318A1
(en)
|
2003-10-31 |
2005-06-02 |
Hudyma Thomas W. |
Inhibitors of HCV replication
|
US7132504B2
(en)
|
2003-11-12 |
2006-11-07 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
WO2005054450A1
(en)
|
2003-12-01 |
2005-06-16 |
Vertex Pharmaceuticals Incorporated |
Compositions comprising fetal liver cells and methods useful for hcv infection
|
CA2549851C
(en)
|
2004-01-21 |
2012-09-11 |
Boehringer Ingelheim International Gmbh |
Macrocyclic peptides active against the hepatitis c virus
|
AU2005212257A1
(en)
|
2004-02-04 |
2005-08-25 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
|
US20050187192A1
(en)
|
2004-02-20 |
2005-08-25 |
Kucera Pharmaceutical Company |
Phospholipids for the treatment of infection by togaviruses, herpes viruses and coronaviruses
|
US7582770B2
(en)
|
2004-02-20 |
2009-09-01 |
Boehringer Ingelheim International Gmbh |
Viral polymerase inhibitors
|
ATE438622T1
(de)
|
2004-02-27 |
2009-08-15 |
Schering Corp |
3,4-(cyclopentyl)kondensierte prolinverbindungen als inhibitoren der ns3-serinprotease des hepatitis-c-virus
|
KR101135765B1
(ko)
|
2004-03-12 |
2012-04-23 |
버텍스 파마슈티칼스 인코포레이티드 |
아스파르트산 아세탈 카스파아제 억제제의 제조를 위한방법 및 중간체
|
US20050249702A1
(en)
|
2004-05-06 |
2005-11-10 |
Schering Corporation |
(1R,2S,5S)-N-[(1S)-3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[(2S)-2-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide as inhibitor of hepatitis C virus NS3/NS4a serine protease
|
BRPI0511900A
(pt)
|
2004-06-08 |
2008-01-22 |
Vertex Pharma |
composições farmacêuticas
|
US7550559B2
(en)
|
2004-08-27 |
2009-06-23 |
Schering Corporation |
Acylsulfonamide compounds as inhibitors of hepatitis C virus NS3 serine protease
|
CN102160891A
(zh)
|
2004-10-01 |
2011-08-24 |
威特克斯医药股份有限公司 |
Hcv ns3-ns4a蛋白酶抑制
|
TW201424733A
(zh)
|
2004-10-29 |
2014-07-01 |
Vertex Pharma |
劑量型式
|
US7863274B2
(en)
|
2005-07-29 |
2011-01-04 |
Concert Pharmaceuticals Inc. |
Deuterium enriched analogues of tadalafil as PDE5 inhibitors
|
AU2006275413B2
(en)
*
|
2005-08-02 |
2012-07-19 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of serine proteases
|
EP2357170A1
(en)
|
2005-08-19 |
2011-08-17 |
Vertex Pharmaceuticals Incorporated |
Processes and intermediates
|
AR055395A1
(es)
*
|
2005-08-26 |
2007-08-22 |
Vertex Pharma |
Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
|
US7705138B2
(en)
|
2005-11-11 |
2010-04-27 |
Vertex Pharmaceuticals Incorporated |
Hepatitis C virus variants
|
JP5436864B2
(ja)
|
2006-02-27 |
2014-03-05 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Vx−950を含む共結晶体およびそれを含む医薬組成物
|
EP1993993A1
(en)
|
2006-03-16 |
2008-11-26 |
Vertex Pharmaceuticals Incorporated |
Processes and intermediates for preparing steric compounds
|
EP1993994A2
(en)
|
2006-03-16 |
2008-11-26 |
Vertex Pharmceuticals Incorporated |
Deuterated hepatitis c protease inhibitors
|
EA018811B1
(ru)
|
2006-03-20 |
2013-10-30 |
Вертекс Фармасьютикалз Инкорпорейтед |
Способы получения твердой дисперсии лекарственного средства и твердые дисперсии лекарственного средства, полученные этим способом
|
AU2007226983A1
(en)
|
2006-03-20 |
2007-09-27 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions
|
ATE481089T1
(de)
|
2006-05-31 |
2010-10-15 |
Vertex Pharma |
Orale formulierungen mit kontrollierter freisetzung eines interleukin-1-beta-converting- enzyme inhibitors
|